GMP Facility
Cell Immunotherapy and Gene Therapy (CITGT) Good Manufacturing Practice (GMP) Facility
The Cell Immunotherapy and Gene Therapy GMP facility supports the manufacture of investigational new drug (IND) products for principal investigators under FDA rules and regulations.
The facility consists of 3,000 square feet and is located on the North Campus of Roger Williams Medical Center. The facility was established in 2001 to support the adoptive T-cell therapy program of immunotherapy and also serve as a core for the Roger Williams’ cancer center, surgical immunotherapy, gene therapy, and biotherapeutic development programs. Our specialized GMP facility is one of the eight facilities in nation that support adoptive T-cell therapy based phase I and phase II clinical trials that require gene modified T-cells or bispecific antibody conjugated T-cells.
GMP Facility: Features
Two positive pressure ISO Class 6 Clean rooms with access to an additional suite to extend capacity
Positive pressure ISO Class 7 Ante room
Meet or exceed FDA requirements for air flow
24/7 monitoring, alarm system for critical equipment
In-built sterilization capability in GMP suites and in material quarantine room
Restricted key code access to facility and GMP suites
Separate process development lab for optimization
Highly knowledgeable and trained team to support regulatory, QA, manufacturing and QC functions
Established SOPs for laboratory controls and MBR for manufacturing control and record keeping
GMP Facility: Equipments
Bio-safety Cabinets
Laminar Flow Work Station
CO2 Incubators (reach-in)#
Wave Bioreactors
Liquid Nitrogen Freezers#
4oC refrigerators#
-80oC Freezers#
-20oC Freezers#
Cell Harvester
Sterile Tube Sealer
Sterile Tube Connector
Peristaltic Pump
ELISA plate reader
Radioactivity room
Microscopes
Centrifuge
(# = Equipment on real-time monitoring and alarm system)
GMP Facility: Services and Capabilities
Develop and validate SOPs, MBR, forms etc.
Support CMC section for IND, Quality Assurance, regulatory, audits, review, Quality Control
Produce gene modified T-cell (capacity > 1011 cells/ batch)
Gene Transfer of cells with viral vectors
Bispecific antibodies production by biochemical conjugation
Biochemically conjugated-T cell (capacity > 1011 cells/ batch)
Pre and post treatment cell banking
QC test for gene expression, endotoxin, viability, cytotoxicity
For inquiries regarding clinical trials, research collaborations, and cell production, please contact:
Prajna Guha, PhD
Research Scientist/Production & Compliance Supervisor
401-456-5783
prajna.guha@chartercare.org
Anthony Bais, PhD
Research Scientist/Biologic Product Development Supervisor
401-456-6471
anthony.bais@chartercare.org